[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fpHxDB_bqUDdXxFbzVXXIUR6ZfWbMGd2TWT65yJDcY5s":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":58,"rows":65},"Oswaldo Cruz Foundation",[4],41,false,5,9,46958,6,16,[14,16,19,21,23,26,28,30],{"name":15,"count":8},"HIV Infections",{"name":17,"count":18},"Hepatitis C",3,{"name":20,"count":18},"Schistosomiasis",{"name":22,"count":18},"Tuberculosis",{"name":24,"count":25},"Cervical Intraepithelial Neoplasia",2,{"name":27,"count":25},"Liver Diseases",{"name":29,"count":25},"Pregnancy",{"name":31,"count":25},"Schistosomiasis Mansoni",[33,38,43,48,53],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT03132311","Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals","2018-12","Yellow Fever vaccination",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05507671","The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines","2023-07-31","BCG (Bacillus Calmette-Guérin) vaccine",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT07584122","Improving Access to PrEP (HIV Prevention Medication) for People in Underserved Areas of Rio de Janeiro","2026-12","Oral Pre-Exposure Prophylaxis",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT07500415","Doxi-Rio: Study on the Use of Doxycycline to Prevent Sexually Transmitted Infections in Rio de Janeiro","2027-10","Doxycycline",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT07497594","ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention","2029-02","Lenacapavir long-acting",[59,60,61,62,63,64],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[66,90,113,138,161,179,198,227,245,270,288,314,332,357,382,400,425,462,492,515,542,560,586,621,643,670,695,719,742],{"intervention":37,"totalTrials":67,"cells":68},1,{"EARLY_PHASE1":69,"PHASE1":72,"PHASE2":74,"PHASE3":76,"PHASE4":78,"NA":88},{"trials":70,"activeCount":71},[],0,{"trials":73,"activeCount":71},[],{"trials":75,"activeCount":71},[],{"trials":77,"activeCount":71},[],{"trials":79,"activeCount":67,"soonestReadout":36},[80],{"nctId":34,"briefTitle":35,"status":81,"phases":82,"primaryCompletion":36,"completion":83,"start":84,"enrollment":85,"conditions":86,"interventions":87},"RECRUITING",[63],"2028-12","2017-05-29",400,[15],[37],{"trials":89,"activeCount":71},[],{"intervention":42,"totalTrials":67,"cells":91},{"EARLY_PHASE1":92,"PHASE1":94,"PHASE2":96,"PHASE3":98,"PHASE4":109,"NA":111},{"trials":93,"activeCount":71},[],{"trials":95,"activeCount":71},[],{"trials":97,"activeCount":71},[],{"trials":99,"activeCount":67,"soonestReadout":41},[100],{"nctId":39,"briefTitle":40,"status":101,"phases":102,"primaryCompletion":41,"completion":103,"start":104,"enrollment":105,"conditions":106,"interventions":108},"ACTIVE_NOT_RECRUITING",[62],"2025-12-31","2021-05-27",556,[107],"COVID-19",[42],{"trials":110,"activeCount":71},[],{"trials":112,"activeCount":71},[],{"intervention":52,"totalTrials":67,"cells":114},{"EARLY_PHASE1":115,"PHASE1":117,"PHASE2":119,"PHASE3":121,"PHASE4":123,"NA":125},{"trials":116,"activeCount":71},[],{"trials":118,"activeCount":71},[],{"trials":120,"activeCount":71},[],{"trials":122,"activeCount":71},[],{"trials":124,"activeCount":71},[],{"trials":126,"activeCount":67,"soonestReadout":51},[127],{"nctId":49,"briefTitle":50,"status":81,"phases":128,"primaryCompletion":51,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":137},[64],"2028-05","2025-10-28",200,[133,134,135,136,15],"Sexually Transmitted Diseases","Syphilis","Gonorrhea","Chlamydia Infections",[52],{"intervention":57,"totalTrials":67,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":150},{"trials":141,"activeCount":71},[],{"trials":143,"activeCount":71},[],{"trials":145,"activeCount":71},[],{"trials":147,"activeCount":71},[],{"trials":149,"activeCount":71},[],{"trials":151,"activeCount":67,"soonestReadout":56},[152],{"nctId":54,"briefTitle":55,"status":81,"phases":153,"primaryCompletion":56,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":159},[64],"2029-09","2026-02-03",1500,[158],"Contact With or Exposure to Human Immunodeficiency Virus",[57,160],"Tenofovi-Emtricitabine (TDF\u002FFTC)",{"intervention":160,"totalTrials":67,"cells":162},{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":169,"PHASE4":171,"NA":173},{"trials":164,"activeCount":71},[],{"trials":166,"activeCount":71},[],{"trials":168,"activeCount":71},[],{"trials":170,"activeCount":71},[],{"trials":172,"activeCount":71},[],{"trials":174,"activeCount":67,"soonestReadout":56},[175],{"nctId":54,"briefTitle":55,"status":81,"phases":176,"primaryCompletion":56,"completion":154,"start":155,"enrollment":156,"conditions":177,"interventions":178},[64],[158],[57,160],{"intervention":47,"totalTrials":67,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":189,"NA":191},{"trials":182,"activeCount":71},[],{"trials":184,"activeCount":71},[],{"trials":186,"activeCount":71},[],{"trials":188,"activeCount":71},[],{"trials":190,"activeCount":71},[],{"trials":192,"activeCount":67,"soonestReadout":46},[193],{"nctId":44,"briefTitle":45,"status":81,"phases":194,"primaryCompletion":46,"completion":46,"start":195,"enrollment":85,"conditions":196,"interventions":197},[64],"2025-09-01",[15],[47],{"intervention":199,"totalTrials":67,"cells":200},"Intravenous Immunoglobulin",{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":225},{"trials":202,"activeCount":71},[],{"trials":204,"activeCount":71},[],{"trials":206,"activeCount":71},[],{"trials":208,"activeCount":71},[],{"trials":210,"activeCount":71},[211],{"nctId":212,"briefTitle":213,"status":214,"phases":215,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":223},"NCT00288600","Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease","COMPLETED",[63],"2010-06","2010-08","2006-10",92,[221,222],"Hyperbilirubinemia","Erythroblastosis, Fetal",[199,224],"Normal saline solution",{"trials":226,"activeCount":71},[],{"intervention":224,"totalTrials":67,"cells":228},{"EARLY_PHASE1":229,"PHASE1":231,"PHASE2":233,"PHASE3":235,"PHASE4":237,"NA":243},{"trials":230,"activeCount":71},[],{"trials":232,"activeCount":71},[],{"trials":234,"activeCount":71},[],{"trials":236,"activeCount":71},[],{"trials":238,"activeCount":71},[239],{"nctId":212,"briefTitle":213,"status":214,"phases":240,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":241,"interventions":242},[63],[221,222],[199,224],{"trials":244,"activeCount":71},[],{"intervention":246,"totalTrials":67,"cells":247},"Specialist - Epclusa 400Mg-100Mg",{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":256,"NA":268},{"trials":249,"activeCount":71},[],{"trials":251,"activeCount":71},[],{"trials":253,"activeCount":71},[],{"trials":255,"activeCount":71},[],{"trials":257,"activeCount":71},[258],{"nctId":259,"briefTitle":260,"status":261,"phases":262,"primaryCompletion":103,"completion":103,"start":263,"enrollment":264,"conditions":265,"interventions":266},"NCT06306300","Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)","UNKNOWN",[63],"2022-07-04",30000,[17],[246,267],"Non- specialist - Epclusa 400Mg-100Mg",{"trials":269,"activeCount":71},[],{"intervention":267,"totalTrials":67,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":280,"NA":286},{"trials":273,"activeCount":71},[],{"trials":275,"activeCount":71},[],{"trials":277,"activeCount":71},[],{"trials":279,"activeCount":71},[],{"trials":281,"activeCount":71},[282],{"nctId":259,"briefTitle":260,"status":261,"phases":283,"primaryCompletion":103,"completion":103,"start":263,"enrollment":264,"conditions":284,"interventions":285},[63],[17],[246,267],{"trials":287,"activeCount":71},[],{"intervention":289,"totalTrials":67,"cells":290},"Praziquantel 60 mg\u002Fkg",{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":299,"NA":312},{"trials":292,"activeCount":71},[],{"trials":294,"activeCount":71},[],{"trials":296,"activeCount":71},[],{"trials":298,"activeCount":71},[],{"trials":300,"activeCount":71},[301],{"nctId":302,"briefTitle":303,"status":214,"phases":304,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":310},"NCT00403611","Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil",[63],"2007-10","2008-05","2006-03",196,[31],[289,311],"Praziquantel 40 mg\u002Fkg",{"trials":313,"activeCount":71},[],{"intervention":311,"totalTrials":67,"cells":315},{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":322,"PHASE4":324,"NA":330},{"trials":317,"activeCount":71},[],{"trials":319,"activeCount":71},[],{"trials":321,"activeCount":71},[],{"trials":323,"activeCount":71},[],{"trials":325,"activeCount":71},[326],{"nctId":302,"briefTitle":303,"status":214,"phases":327,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":328,"interventions":329},[63],[31],[289,311],{"trials":331,"activeCount":71},[],{"intervention":333,"totalTrials":67,"cells":334},"efavirenz",{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":343,"NA":355},{"trials":336,"activeCount":71},[],{"trials":338,"activeCount":71},[],{"trials":340,"activeCount":71},[],{"trials":342,"activeCount":71},[],{"trials":344,"activeCount":71},[345],{"nctId":346,"briefTitle":347,"status":348,"phases":349,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":353,"interventions":354},"NCT00533390","Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg","TERMINATED",[63],"2012-10","2007-01",130,[22,15],[333],{"trials":356,"activeCount":71},[],{"intervention":358,"totalTrials":67,"cells":359},"Lopinavir \u002F ritonavir",{"EARLY_PHASE1":360,"PHASE1":362,"PHASE2":364,"PHASE3":366,"PHASE4":368,"NA":380},{"trials":361,"activeCount":71},[],{"trials":363,"activeCount":71},[],{"trials":365,"activeCount":71},[],{"trials":367,"activeCount":71},[],{"trials":369,"activeCount":71},[370],{"nctId":371,"briefTitle":372,"status":214,"phases":373,"primaryCompletion":374,"completion":374,"start":375,"enrollment":376,"conditions":377,"interventions":378},"NCT00605098","Pharmacokinetics of the Tablet Formulation of Lopinavir\u002Fr as Standard and Increased Dosage During Pregnancy",[63],"2012-07","2008-02",60,[15,29],[358,379],"Lopinavir\u002Fritonavir",{"trials":381,"activeCount":71},[],{"intervention":379,"totalTrials":67,"cells":383},{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":390,"PHASE4":392,"NA":398},{"trials":385,"activeCount":71},[],{"trials":387,"activeCount":71},[],{"trials":389,"activeCount":71},[],{"trials":391,"activeCount":71},[],{"trials":393,"activeCount":71},[394],{"nctId":371,"briefTitle":372,"status":214,"phases":395,"primaryCompletion":374,"completion":374,"start":375,"enrollment":376,"conditions":396,"interventions":397},[63],[15,29],[358,379],{"trials":399,"activeCount":71},[],{"intervention":401,"totalTrials":67,"cells":402},"Lopinavir",{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":407,"PHASE3":409,"PHASE4":411,"NA":423},{"trials":404,"activeCount":71},[],{"trials":406,"activeCount":71},[],{"trials":408,"activeCount":71},[],{"trials":410,"activeCount":71},[],{"trials":412,"activeCount":71},[413],{"nctId":414,"briefTitle":415,"status":214,"phases":416,"primaryCompletion":417,"completion":417,"start":418,"enrollment":419,"conditions":420,"interventions":422},"NCT00771498","An Evaluation of the Pharmacological Interaction of Lopinavir\u002Fr and Rifampin",[63],"2012-12","2008-11",30,[421,22],"HIV Infection",[401],{"trials":424,"activeCount":71},[],{"intervention":426,"totalTrials":25,"cells":427},"Meglumine antimoniate",{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":434,"PHASE4":458,"NA":460},{"trials":429,"activeCount":71},[],{"trials":431,"activeCount":71},[],{"trials":433,"activeCount":71},[],{"trials":435,"activeCount":71},[436,448],{"nctId":437,"briefTitle":438,"status":261,"phases":439,"primaryCompletion":440,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":447},"NCT01301937","Low Antimonial Dosage in American Mucosal Leishmaniasis",[61,62],"2020-12","2021-12","2008-10",76,[445,446],"Mucosal Leishmaniasis","Mucocutaneous Leishmaniasis",[426],{"nctId":449,"briefTitle":450,"status":214,"phases":451,"primaryCompletion":452,"completion":453,"start":442,"enrollment":454,"conditions":455,"interventions":457},"NCT01301924","Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis",[61,62],"2016-04","2017-12",72,[456],"Cutaneous Leishmaniasis",[426],{"trials":459,"activeCount":71},[],{"trials":461,"activeCount":71},[],{"intervention":463,"totalTrials":67,"cells":464},"Lactobacillus rhamnosus GR1 and Lactobacillus reuteri RC-14",{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":471,"PHASE4":488,"NA":490},{"trials":466,"activeCount":71},[],{"trials":468,"activeCount":71},[],{"trials":470,"activeCount":71},[],{"trials":472,"activeCount":71},[473],{"nctId":474,"briefTitle":475,"status":348,"phases":476,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":487},"NCT00303082","Probiotics for the Prevention of Premature Birth and Neonatal Related Morbidity",[62],"2009-01","2009-08","2006-01",645,[482,483,484,485,486],"Bacterial Vaginosis","Premature Birth","Sepsis","Periventricular Leukomalacia","Bronchopulmonary Dysplasia",[463],{"trials":489,"activeCount":71},[],{"trials":491,"activeCount":71},[],{"intervention":493,"totalTrials":67,"cells":494},"Selenium",{"EARLY_PHASE1":495,"PHASE1":497,"PHASE2":499,"PHASE3":501,"PHASE4":511,"NA":513},{"trials":496,"activeCount":71},[],{"trials":498,"activeCount":71},[],{"trials":500,"activeCount":71},[],{"trials":502,"activeCount":71},[503],{"nctId":504,"briefTitle":505,"status":261,"phases":506,"primaryCompletion":507,"completion":440,"start":442,"enrollment":352,"conditions":508,"interventions":510},"NCT00875173","Selenium Treatment and Chagasic Cardiopathy (STCC)",[62],"2016-12",[509],"Chagas Disease",[493],{"trials":512,"activeCount":71},[],{"trials":514,"activeCount":71},[],{"intervention":516,"totalTrials":67,"cells":517},"Chloroquine",{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":524,"PHASE4":538,"NA":540},{"trials":519,"activeCount":71},[],{"trials":521,"activeCount":71},[],{"trials":523,"activeCount":71},[],{"trials":525,"activeCount":71},[526],{"nctId":527,"briefTitle":528,"status":214,"phases":529,"primaryCompletion":530,"completion":531,"start":532,"enrollment":533,"conditions":534,"interventions":536},"NCT02691910","Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine for Plasmodium Vivax Infection",[61,62],"2015-08","2015-09","2014-08",204,[535],"Malaria, Vivax",[516,537],"Primaquine",{"trials":539,"activeCount":71},[],{"trials":541,"activeCount":71},[],{"intervention":537,"totalTrials":67,"cells":543},{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":550,"PHASE4":556,"NA":558},{"trials":545,"activeCount":71},[],{"trials":547,"activeCount":71},[],{"trials":549,"activeCount":71},[],{"trials":551,"activeCount":71},[552],{"nctId":527,"briefTitle":528,"status":214,"phases":553,"primaryCompletion":530,"completion":531,"start":532,"enrollment":533,"conditions":554,"interventions":555},[61,62],[535],[516,537],{"trials":557,"activeCount":71},[],{"trials":559,"activeCount":71},[],{"intervention":561,"totalTrials":67,"cells":562},"artesunate & mefloquine combination",{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":569,"PHASE4":582,"NA":584},{"trials":564,"activeCount":71},[],{"trials":566,"activeCount":71},[],{"trials":568,"activeCount":71},[],{"trials":570,"activeCount":71},[571],{"nctId":572,"briefTitle":573,"status":214,"phases":574,"primaryCompletion":575,"completion":576,"start":577,"enrollment":578,"conditions":579,"interventions":581},"NCT01144702","Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum",[61,62],"2013-04","2014-07","2010-11",163,[580],"Falciparum Malaria",[561],{"trials":583,"activeCount":71},[],{"trials":585,"activeCount":71},[],{"intervention":587,"totalTrials":25,"cells":588},"Sm14",{"EARLY_PHASE1":589,"PHASE1":591,"PHASE2":593,"PHASE3":615,"PHASE4":617,"NA":619},{"trials":590,"activeCount":71},[],{"trials":592,"activeCount":71},[],{"trials":594,"activeCount":71},[595,605],{"nctId":596,"briefTitle":597,"status":214,"phases":598,"primaryCompletion":599,"completion":600,"start":601,"enrollment":419,"conditions":602,"interventions":603},"NCT03041766","Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions",[61],"2017-04-06","2017-06-02","2016-12-06",[20],[587,604],"GLA-SE solution",{"nctId":606,"briefTitle":607,"status":214,"phases":608,"primaryCompletion":609,"completion":610,"start":611,"enrollment":612,"conditions":613,"interventions":614},"NCT03799510","Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children",[61],"2019-07-01","2019-08-07","2018-12-13",95,[20],[587,604],{"trials":616,"activeCount":71},[],{"trials":618,"activeCount":71},[],{"trials":620,"activeCount":71},[],{"intervention":604,"totalTrials":25,"cells":622},{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":627,"PHASE3":637,"PHASE4":639,"NA":641},{"trials":624,"activeCount":71},[],{"trials":626,"activeCount":71},[],{"trials":628,"activeCount":71},[629,633],{"nctId":596,"briefTitle":597,"status":214,"phases":630,"primaryCompletion":599,"completion":600,"start":601,"enrollment":419,"conditions":631,"interventions":632},[61],[20],[587,604],{"nctId":606,"briefTitle":607,"status":214,"phases":634,"primaryCompletion":609,"completion":610,"start":611,"enrollment":612,"conditions":635,"interventions":636},[61],[20],[587,604],{"trials":638,"activeCount":71},[],{"trials":640,"activeCount":71},[],{"trials":642,"activeCount":71},[],{"intervention":644,"totalTrials":67,"cells":645},"Sm14 recombinant vaccine+ GLA-SE adjuvant",{"EARLY_PHASE1":646,"PHASE1":648,"PHASE2":650,"PHASE3":664,"PHASE4":666,"NA":668},{"trials":647,"activeCount":71},[],{"trials":649,"activeCount":71},[],{"trials":651,"activeCount":71},[652],{"nctId":653,"briefTitle":654,"status":261,"phases":655,"primaryCompletion":656,"completion":657,"start":658,"enrollment":659,"conditions":660,"interventions":663},"NCT05658614","Anti-Schistosomiasis Sm14-vaccine in Senegal",[61],"2023-09-15","2023-12-31","2022-07-01",120,[31,661,662],"Schistosomiasis Haematobium","Vaccination; Infection",[644],{"trials":665,"activeCount":71},[],{"trials":667,"activeCount":71},[],{"trials":669,"activeCount":71},[],{"intervention":671,"totalTrials":67,"cells":672},"Adjuvanted vaccine against H1N1 influenza virus",{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":677,"PHASE3":689,"PHASE4":691,"NA":693},{"trials":674,"activeCount":71},[],{"trials":676,"activeCount":71},[],{"trials":678,"activeCount":71},[679],{"nctId":680,"briefTitle":681,"status":214,"phases":682,"primaryCompletion":683,"completion":684,"start":685,"enrollment":686,"conditions":687,"interventions":688},"NCT01155037","Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults",[61],"2012-03","2012-04","2010-03",450,[421],[671,671,671],{"trials":690,"activeCount":71},[],{"trials":692,"activeCount":71},[],{"trials":694,"activeCount":71},[],{"intervention":696,"totalTrials":67,"cells":697},"sm14 antigen plus adjuvant GLA",{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":711,"PHASE3":713,"PHASE4":715,"NA":717},{"trials":699,"activeCount":71},[],{"trials":701,"activeCount":71},[702],{"nctId":703,"briefTitle":704,"status":214,"phases":705,"primaryCompletion":706,"completion":706,"start":707,"enrollment":708,"conditions":709,"interventions":710},"NCT01154049","Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis",[60],"2014-04","2011-03",20,[20],[696],{"trials":712,"activeCount":71},[],{"trials":714,"activeCount":71},[],{"trials":716,"activeCount":71},[],{"trials":718,"activeCount":71},[],{"intervention":720,"totalTrials":67,"cells":721},"Isoniazida",{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":734,"PHASE3":736,"PHASE4":738,"NA":740},{"trials":723,"activeCount":71},[],{"trials":725,"activeCount":71},[726],{"nctId":727,"briefTitle":728,"status":214,"phases":729,"primaryCompletion":442,"completion":730,"start":442,"enrollment":731,"conditions":732,"interventions":733},"NCT02043314","A Bioequivalence Study of Two Different Dosages of Isoniazid Tablet Formulations in Human Healthy Volunteers",[60],"2009-03",28,[22],[720],{"trials":735,"activeCount":71},[],{"trials":737,"activeCount":71},[],{"trials":739,"activeCount":71},[],{"trials":741,"activeCount":71},[],{"intervention":743,"totalTrials":25,"cells":744},"emtricitabine \u002F tenofovir 200\u002F300 mg",{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":751,"PHASE4":753,"NA":765},{"trials":746,"activeCount":71},[],{"trials":748,"activeCount":71},[],{"trials":750,"activeCount":71},[],{"trials":752,"activeCount":71},[],{"trials":754,"activeCount":71},[755],{"nctId":756,"briefTitle":757,"status":261,"phases":758,"primaryCompletion":759,"completion":760,"start":761,"enrollment":659,"conditions":762,"interventions":764},"NCT03220152","Implementation of PrEP to HIV in Brazilian Transgender Women",[63],"2019-07","2020-07","2017-07-10",[763],"HIV, Prevention",[743],{"trials":766,"activeCount":71},[767],{"nctId":768,"briefTitle":769,"status":261,"phases":770,"primaryCompletion":771,"completion":452,"start":772,"enrollment":85,"conditions":773,"interventions":775},"NCT01989611","Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV: A Demonstrative Project.",[64],"2016-03","2014-06",[774],"HIV",[743]]